Genmab — Share Issue/Capital Change 2016

May 18, 2016

Company Announcement

Copenhagen, Denmark; May 18, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) will
increase its share capital by 156,348 shares as a consequence of the exercise
of employee warrants.

The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following price per share of nominally DKK 1:

-- 281 shares at DKK 26.75,
-- 2,600 shares at DKK 31.75,
-- 850 shares at DKK 40.41,
-- 4,375 shares at DKK 45.24,
-- 350 shares at DKK 66.60,
-- 3,000 shares at DKK 67.50,
-- 750 shares at DKK 68.65,
-- 1,250 shares at DKK 79.25,
-- 950 shares at DKK 80.55,
-- 125 shares at DKK 98,
-- 1,250 shares at DKK 129.75,
-- 5,000 shares at DKK 173,
-- 344 shares at DKK 210,
-- 2,800 shares at DKK 215.60,
-- 9,666 shares at DKK 224,
-- 6,749 shares at DKK 225.90,
-- 1,150 shares at DKK 231.50,
-- 5,830 shares at DKK 234,
-- 1,500 shares at DKK 234.75,
-- 1,200 shares at DKK 246,
-- 11,975 shares at DKK 254,
-- 16,050 shares at DKK 272,
-- 7,925 shares at DKK 326.50,
-- 3,625 shares at DKK 329,
-- 1,212 shares at DKK 330,
-- 1,688 shares at DKK 337.40,
-- 49,390 shares at DKK 352.50,
-- 11,844 shares at DKK 364, and
-- 2,619 shares at DKK 466.20.

Proceeds to the company are approximately DKK 43.6 million. The increase
corresponds to approx. 0.3 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares give rights to dividends
and other rights in relation to the company as of subscription, i.e. inter alia
full rights to dividends for the financial year 2016. The new shares will be
listed on Nasdaq Copenhagen after registration with the Danish Business
Authority. Genmab A/S' current share capital amounts to DKK 59,677,584 and will
after the capital increase be DKK 59,833,932. The capital increase is expected
to be finalized shortly.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia
indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated
or double refractory multiple myeloma. Daratumumab is in clinical development
for additional multiple myeloma indications and for non-Hodgkin’s lymphoma.
Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's
technology base consists of validated and proprietary next generation antibody
technologies - the DuoBody® platform for generation of bispecific antibodies,
and the HexaBody® platform which creates effector function enhanced antibodies.
The company intends to leverage these technologies to create opportunities for
full or co-ownership of future products. Genmab has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 23
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark